New digital disease management tool to support lupin growers
NiveshIQ
NSE: LUPIN · Pharma
Lupin Ltd.
₹2,447.00▲ ₹51.20 (+2.14%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on LUPIN. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Lupin Ltd.
Lupin Limited is a leading Indian pharmaceutical company with a diverse portfolio of branded and generic formulations, biosimilars, and active pharmaceutical ingredients (APIs). The company operates in two segments: Pharmaceuticals and Others, and engages in drug discovery, development, production, marketing, and sale of various drugs across therapeutic areas. Lupin has a strong presence in the US and international markets, with a growing presence in emerging markets. Recent developments include solid Q4 results, partnerships with ERN to launch Luforbec for asthma and COPD treatment, and Bernstein's backing of the company's innovation shift. The company's revenue stood at ₹27,958 crore, with a net income of ₹5,333 crore. Lupin's competitive position is strong, driven by its diversified por
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹20,011 Cr +128.60% | ₹22,708 Cr +13.50% | ₹27,046 Cr +19.10% |
| EBITDA Margin | 19.03% | 23.15% | 32.03% |
| Net Profit | ₹1,935 Cr +383.80% | ₹3,306 Cr +70.90% | ₹5,324 Cr +61.00% |
| EPS | ₹42.06 | ₹71.93 | ₹111.00 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Lupin Limited Receives Approval For Diazepam Injection USP, 10 Mg/2 Ml (5 Mg/Ml), Single-Dose Prefilled Syringes In The United States
Lupin Gets US FDA Approval For Diazepam Injection
🔒
+ 3 more stories about Lupin Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹7, 475 Cr, PAT ₹1, 469 Cr, EPS ₹31.96, EBITDA margin 35.1%. Growth context: revenue YoY +31.9%, PAT YoY +87.8%, revenue QoQ +4.3%, PAT QoQ +24.4%. Street verdict: beat, revenue surprise -0.4%, PAT surprise +3.2%.
Recent corporate activity highlights product launches, approvals, and therapy-mix improvement and new product launches a...
FY26 (last completed FY): revenue ₹27, 046 Cr, PAT ₹5, 324 Cr, EBITDA margin 32.0%, EPS ₹111.00. Year-on-year: revenue Y...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for LUPIN
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track LUPIN alongside your other holdings
Unlock full LUPIN research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Lupin Ltd.?
NiveshIQ detects active intelligence signals for Lupin Ltd. (LUPIN) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Lupin Ltd.?
Lupin Ltd. operates in the Pharma sector with a market capitalisation of ₹10,321,566.8L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.